GLP-1 Medications & Cannabis: Every Drug. Every Method. What the Evidence Shows.

GLP-1 medications delay gastric emptying — the process that moves stomach contents into the small intestine where cannabis is absorbed. An edible that normally takes 45–90 minutes to produce effects may take 2–4+ hours on a GLP-1 medication. The effect also tends to be more intense when absorption finally occurs because the dose has been delayed and concentrated. This is a class effect shared by all GLP-1 medications regardless of brand.

From a GLP-1 gastric absorption standpoint, yes. Smoked and vaped cannabis are absorbed through the lungs and are not affected by GLP-1 gastric slowing. Onset is predictable (1–10 minutes) regardless of GLP-1 use. Edibles, by contrast, require GI transit and are subject to significant absorption delay. However, inhaled cannabis carries its own concerns: pulmonary risk from combustion or vaping-associated injury, and THC's appetite stimulation which counteracts GLP-1 appetite suppression. There is no universally safer method — the risk profile varies by drug, method, individual health, and purpose of GLP-1 use.

THC directly stimulates appetite through CB1 receptor activation in the hypothalamus — the same brain region where GLP-1 medications suppress appetite. For patients using GLP-1 medications for weight management (Wegovy, Zepbound, Saxenda), THC-driven food cravings can undermine therapeutic progress. This is a pharmacodynamic conflict that applies regardless of cannabis route. Whether the magnitude of THC's appetite effect is sufficient to offset GLP-1's effect in an individual patient depends on dose, frequency, and product potency. Patients using GLP-1 for weight management who use cannabis regularly should discuss this with their prescriber.

Yes — significantly. Foundayo (orforglipron) is an oral daily pill, unlike all other GLP-1 medications which are injectable. Both Foundayo and oral cannabis products (edibles, CBD oil, tinctures) are processed through the GI tract simultaneously, creating a direct competition for GI absorption that does not exist with injectable GLP-1 medications. Foundayo must be taken fasting with only water for at least 30 minutes before food. Oral cannabis products taken near the Foundayo dosing window directly conflict with these requirements. For Foundayo patients, inhaled cannabis (smoking, vaping) is the lower-risk cannabis method from a GI perspective.

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist in Phase 3 clinical trials as of June 2026 — not FDA-approved and available only through trials. No brand name has been assigned. Cannabis interaction assessment for retatrutide is mechanism-based extrapolation from the GLP-1 class. The gastric slowing mechanism applies (likely pronounced given triple agonist activity), meaning oral cannabis absorption delays are expected. THC appetite stimulation conflict with weight management goals also applies. No retatrutide-specific cannabis interaction data is published. Trial participants using cannabis should disclose this to the trial site.